AstraZeneca hikes full-year forecast as Nexium holds its own, Brilinta delivers

Tracy Staton AstraZeneca has so far weathered the Nexium patent cliff well enough to actually raise its full-year sales forecast for 2015. Its Brilinta growth strategy appears to be ...

With Opsumit launch rolling, Actelion doesn’t ‘need’ M&A: CEO

Carly Helfand Back in 2013, Actelion launched Opsumit, a new-and-improved pulmonary arterial hypertension drug it hoped would help make up sales for its aging Tracleer. And so far, ...

Kite nails down TCR IP in new licensing pact

John Carroll Kite Pharma has moved to cement its control of some of the IP behind its work on T cell receptor-based product candidates that zero in on MAGE A3 and A3/A6 antigens. FierceBiotech ...

Pfizer responds to FiercePharma

Alok Saboo Tracy Staton wrote an article on Thursday, based on a piece in Forbes. Pfizer took exception to our article and sent a statement. FiercePharma News

Strongbridge raises $25M in a downsized IPO

Damian Garde Drug developer Strongbridge Biopharma cleared $ 25 million in an IPO, bringing in less than a third of the cash it once sought as biotech companies continue to struggle ...

Biotech notches another $2B VC quarter, but can it last?

Damian Garde Biotech venture capital investments remain on pace for a record year after racking up another $ 2 billion in the third quarter, but some current shakiness in the public ...

Allergan plots 117 job cuts in the wake of Kythera buyout

Tracy Staton The job-cutting ax has been hovering over Kythera Biopharmaceuticals ever since Allergan agreed to buy the company in April. Now, that ax is getting ready to fall. FiercePharma ...

Adaptimmune pockets GSK payouts after tripling size of TCR trial

Nick Paul Taylor Adaptimmune has bagged two milestones from GlaxoSmithKline. The checks landed in Adaptimmune's bank account after it tripled the size of a Phase I/II synovial sarcoma ...

Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1

Eric Palmer The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects ...

Novo Nordisk launches diabetes ‘dream team’ contest with NBA star as a prize

Carly Helfand Former NBA star Dominique Wilkins is not just a spokesman for Novo Nordisk's Victoza. He's also a prize in a Type 2 diabetes sweepstakes the drugmaker is rolling ...

Cannabis patch startup pulls off a $42M IPO to fund drugs for epilepsy, pain

Damian Garde Pennsylvania drugmaker Zynerba Pharmaceuticals is making its way to Wall Street with some cannabis-derived treatments for central nervous system disorders, raising $ 42 ...

Celgene buys into GlobeImmune’s cancer immunotherapy

Damian Garde GlobeImmune, reeling from a costly clinical failure, secured a commitment from long-time partner Celgene to collaborate on a new cancer immunotherapy. FierceBiotech News
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS